Insider trade

Officer sold ~$3.46M of CYTK shares in the open market

Traded Dec 5, 2025 · Filed Dec 5, 2025

Why it stands out

Cytokinetics's Chief Commercial Officer sold $3.46M of Cytokinetics shares. It happened by itself, for taxes or pay.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$1M+Pre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$3,461,452

Shares × reported transaction price

Timing vs results

30 days after results of Nov 5, 2025, 81 days before results of Feb 24, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Filing box checked: sold under a Rule 10b5-1 plan

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−3.1%	−0.4%	−2.6%
30 days	+2.0%	+0.9%	+1.1%
90 days	−2.7%	−0.8%	−1.9%
180 days	+5.9%	+8.1%	−2.3%

Past results only. Not a forecast.

Automatic sale9mo ago

9mo ago

Derivative exercise or conversion — not an open-market buy.

Automatic sale9mo ago